• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Chemotherapy for prostate cancer: small steps or leaps and bounds? No huzzahs just yet!

作者信息

Raghavan D

出版信息

Br J Cancer. 2004 Sep 13;91(6):1003-4. doi: 10.1038/sj.bjc.6602157.

DOI:10.1038/sj.bjc.6602157
PMID:15475939
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2747692/
Abstract
摘要

相似文献

1
Chemotherapy for prostate cancer: small steps or leaps and bounds? No huzzahs just yet!前列腺癌化疗：小步前行还是飞跃发展？现在还无需欢呼！
Br J Cancer. 2004 Sep 13;91(6):1003-4. doi: 10.1038/sj.bjc.6602157.
2
Enzymatic activation of prodrugs by prostate-specific antigen: targeted therapy for metastatic prostate cancer.前列腺特异性抗原对前体药物的酶促激活：转移性前列腺癌的靶向治疗
Cancer J Sci Am. 1998 May;4 Suppl 1:S15-21.
3
Radiopharmaceutical and chemotherapy combinations in metastatic castrate-resistant prostate cancer: a new beginning?转移性去势抵抗性前列腺癌的放射性药物与化疗联合应用：新的开端？
J Clin Oncol. 2009 May 20;27(15):2417-8. doi: 10.1200/JCO.2008.21.4460. Epub 2009 Apr 13.
4
[Topics of prostate cancer].[前列腺癌的主题]
Gan To Kagaku Ryoho. 2009 Jan;36(1):43-6.
5
Chemotherapy for advanced prostate cancer: docetaxel and beyond.晚期前列腺癌的化疗：多西他赛及其他进展
Hematol Oncol Clin North Am. 2006 Aug;20(4):935-46, x. doi: 10.1016/j.hoc.2006.03.004.
6
Suppression of androgen-independent prostate cancer cell aggressiveness by FTY720: validating Runx2 as a potential antimetastatic drug screening platform.FTY720抑制雄激素非依赖性前列腺癌细胞的侵袭性：验证Runx2作为潜在的抗转移药物筛选平台
Clin Cancer Res. 2009 Jul 1;15(13):4322-35. doi: 10.1158/1078-0432.CCR-08-3157. Epub 2009 Jun 9.
7
[Treatment of prostate cancer].[前列腺癌的治疗]
Orv Hetil. 2005 Aug 28;146(35):1839-42.
8
[What is the objective of second-line chemotherapy after failure of first-line chemotherapy in hormone-resistant metastatic prostate?].[激素抵抗性转移性前列腺癌一线化疗失败后二线化疗的目的是什么？]
Prog Urol. 2006 Jun;16(3):320-3.
9
[Prostatic cancer].[前列腺癌]
Prog Urol. 2004 Nov;14(4 Suppl 1):913, 915-55.
10
Intermittent chemotherapy for metastatic hormone refractory prostate cancer.转移性激素难治性前列腺癌的间歇性化疗
Crit Rev Oncol Hematol. 2007 Mar;61(3):243-54. doi: 10.1016/j.critrevonc.2006.10.002. Epub 2006 Dec 11.

引用本文的文献

1
Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer.纳米载体共递送多西他赛和阿霉素用于前列腺癌的协同治疗
Front Pharmacol. 2019 Dec 18;10:1436. doi: 10.3389/fphar.2019.01436. eCollection 2019.
2
Evolving perspectives of the role of novel agents in androgen-independent prostate cancer.新型药物在雄激素非依赖性前列腺癌中作用的不断演变的观点。
Indian J Urol. 2008 Jul;24(3):303-8. doi: 10.4103/0970-1591.42609.

本文引用的文献

1
Is there a role for chemotherapy in prostate cancer?化疗在前列腺癌治疗中是否有作用？
Br J Cancer. 2004 Sep 13;91(6):1005-11. doi: 10.1038/sj.bjc.6601850.
2
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.局部晚期前列腺癌患者立即进行雄激素抑制和外照射的长期结果（一项欧洲癌症研究与治疗组织的研究）：一项III期随机试验
Lancet. 2002 Jul 13;360(9327):103-6. doi: 10.1016/s0140-6736(02)09408-4.
3
Chemotherapy for hormone-refractory prostate cancer: beauty is in the eye of the beholder.激素难治性前列腺癌的化疗：美在观者眼中。
Prostate. 2000 Oct 1;45(2):184-93. doi: 10.1002/1097-0045(20001001)45:2<184::aid-pros13>3.0.co;2-k.
4
Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points.米托蒽醌联合泼尼松治疗有症状的激素抵抗性前列腺癌的经济学评价：基于一项有姑息治疗终点的加拿大随机试验
J Clin Oncol. 1998 Jun;16(6):2272-9. doi: 10.1200/JCO.1998.16.6.2272.
5
Prostate cancer, populations, politicians and power.前列腺癌、人群、政治家与权力。
Eur J Cancer. 1997 Mar;33(3):329-30. doi: 10.1016/s0959-8049(97)89001-6.
6
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.米托蒽醌联合泼尼松或单用泼尼松治疗有症状的激素抵抗性前列腺癌的化疗：一项以姑息治疗为终点的加拿大随机试验
J Clin Oncol. 1996 Jun;14(6):1756-64. doi: 10.1200/JCO.1996.14.6.1756.